Immunomodulators, biologics not linked to higher MACE risk in older adults with IBD
-
July 27
A Medicare claims study found no statistically significant difference in MACE risk compared with 5-ASA therapy.
Browse By
Biliary Tract
Colon
Esophagus
Liver
Pancreas
Small Bowel
Stomach
The GI hospitalist: A practice-changing health care opportunity
-
April 23
-
by Vasili Kalas, MD, PhD
The model is reshaping inpatient care, despite slow national adoption.
Pancreatic cystic lesions: A case-based approach
-
April 17
-
by Ross C.D. Buerlein, MD , Himesh B. Zaver, MD , Vanessa M. Shami, MD
Dr. Vanessa Shami, along with Drs. Ross Buerlein and Himesh Zaver, describe characteristic cyst findings on cross-sectional and endoscopic sonographic imaging, fluid analysis results, and management.
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
February 1
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
The Latest
Immunomodulators, biologics not linked to higher MACE risk in older adults with IBD
-
by Olivia Anderson
A Medicare claims study found no statistically significant difference in MACE risk compared with 5-ASA therapy.
Liver cancer risk falls but persists after 10 years of hepatitis B therapy
-
by Meg Barbor
Long-term PAGE-B cohort data suggest patients with chronic hepatitis B remain at risk for hepatocellular carcinoma beyond 10 years of entecavir or tenofovir, despite a significant drop in incidence.
First-line infliximab delays additional biologics in pediatric Crohn's disease
-
by Doug Brunk
Early infliximab didn't raise five-year remission rates, but it postponed the need for additional biologic therapy.
H. pylori tied to higher colorectal cancer risk in Chinese trial cohorts
-
by Meg Barbor
Treatment was associated with lower long-term risk in one cohort, but not overall in a larger cohort with shorter follow-up.
Dye-free imaging matches dye method in IBD surveillance, study finds
-
by Jess Allerton
In a retrospective cohort, linked color imaging detected precancerous and cancerous lesions about as often as dye-chromoendoscopy while trimming roughly three minutes from withdrawal time.
